Timber Pharmaceuticals Announces Adjournment of Annual Meeting

Rhea-AI Summary

Timber Pharmaceuticals, Inc. (TMBR) announced that the 2021 Annual Meeting of Stockholders was convened without a quorum on June 3, 2021, leading to its adjournment. The meeting is rescheduled for July 1, 2021, at 1:00 p.m. ET, allowing shareholders more time to vote. The record date remains April 12, 2021. Timber Pharmaceuticals focuses on developing treatments for rare dermatologic diseases, including congenital ichthyosis and scleroderma.

Positive

• Company holds a focus on treatments for rare dermatologic diseases, which may attract niche market interest.

Negative

• The failure to establish a quorum could indicate shareholder disengagement or dissatisfaction.

Basking Ridge, NJ, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 3, 2021 its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was convened without a quorum. As a result, in order to provide stockholders additional time within which to vote their eligible shares to establish a quorum, the Annual Meeting was adjourned.

The adjourned meeting will be held at 1:00 p.m. ET on Thursday, July 1, 2021 at the following url: www.virtualshareholdermeeting.com/TMBR2021.  The record date for the Annual Meeting remains April 12, 2021.

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com.

For more information, contact:

Timber Pharmaceuticals, Inc. 
John Koconis 
Chairman and Chief Executive Officer
jkoconis@timberpharma.com

Investor Relations:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com

Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com

FAQ

When is Timber Pharmaceuticals' adjourned Annual Meeting?

The adjourned Annual Meeting will be held on July 1, 2021, at 1:00 p.m. ET.

Why was Timber Pharmaceuticals' Annual Meeting adjourned?

The Annual Meeting was adjourned due to the lack of a quorum.

What is the purpose of Timber Pharmaceuticals' Annual Meeting?

The Annual Meeting allows stockholders to vote on important corporate matters.

What is the record date for Timber Pharmaceuticals' Annual Meeting?

The record date for the Annual Meeting remains April 12, 2021.

What diseases does Timber Pharmaceuticals focus on?

Timber Pharmaceuticals focuses on treatments for rare dermatologic diseases, including congenital ichthyosis and scleroderma.